Though a 7.7% falloff in shares of Vivus (VVUS) isn't cause for alarm after they ran up 83% over...

|By:, SA News Editor

Though a 7.7% falloff in shares of Vivus (VVUS) isn't cause for alarm after they ran up 83% over the last 5 trading sessions, Forbes is out with a cautionary take on the company's new obesity drug that is all the rage. "It seems intuitively obvious that the market for an obesity drug would be vast. But the reality is that obesity drugs have never sold in Lipitor-like numbers."